PHILADELPHIA, Dec. 13, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that it has concluded an agreement with a major vaccine manufacturer in Japan for the use of the Company’s experimental drug Ampligen(r) as an immune enhancer to influenza vaccines. The Company’s agreement with BIKEN (the non-profit operational arm of the Foundation for Microbial Diseases of Osaka University) is part of a 3 party agreement to develop an effective influenza vaccine for Japan and utilizes vast resources of the National Institute of Infectious Diseases of Japan (“NIID”).
